CSAClinical-Stage Asset Intelligence
Catalyst calendar Get the data
Home / Genmab A/S (GMAB) / acasunlimab
Forward catalyst · GMAB

acasunlimab

Sponsor Genmab A/S · listed as GMAB

READOUT Phase 3 Confidence: medium Source: clinicaltrials

acasunlimab is a drug asset sponsored by Genmab A/S, listed as GMAB. CSA tracks 1 forward catalyst for it — the nearest is a readout expected Jul 30, 2027 (day precision, medium confidence), tied to trial NCT06635824. That trial is in Phase 3 and currently active not recruiting, studying PD-L1-positive, Locally Advanced (Unresectable Stage IIIB/C) or Metastatic NSCLC.

Next catalyst

Event typeREADOUT
Expected date2027-07-30
As disclosedJul 30, 2027
Date precisionday
Confidencemedium
Verify at source →

Trial & sponsor

Trial (NCT)NCT06635824
PhasePHASE3
StatusACTIVE_NOT_RECRUITING
Lead sponsorGenmab
Listed asGMAB
Condition(s)PD-L1-positive, Locally Advanced (Unresectable Stage IIIB/C) or Metastatic NSCLC
!

Data, not investment advice. CSA is information, not a recommendation to buy, sell or hold any security. Estimated catalyst dates routinely slip and are graded by confidence — verify against the source link before acting.

This page is one record from the free CSA sample. The full snapshot covers active, industry-sponsored Phase 3 trials in cardiometabolic, oncology and immunology. Every forward catalyst carries its date, confidence grade and source link, and is linked to its sponsor's ticker when the sponsor is a listed company.

Get the full dataset — $499 →   More GMAB catalysts

Related catalysts and sponsor